Company & Sponsor Intelligence
Zealand University Hospital
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials5
Recruiting1
Completed4
Countries1
Therapeutic footprint
alzheimersdepressionmultiple_sclerosisstroke
Indexed studies
NCT04117178Monitoring Anti-Dementia Drugs by Serum Levels
alzheimers · DenmarkPHASE4
alzheimers · DenmarkPHASE4
NCT04574921Study on Safety, Feasibility and Neural Activation of Non-Invasive Light Therapy System
alzheimers · DenmarkNA
alzheimers · DenmarkNA
NCT07304375Effects of Exercise and Sleep on Motor Learning and Functional Abilities in Multiple Sclerosis
multiple_sclerosis · DenmarkNA
multiple_sclerosis · DenmarkNA
NCT02451293The Effect of MElatonin on Depression, Anxiety, CIrcadian and Sleep Disturbances in Patients After Acute Myocardial Syndrome
depression · DenmarkPHASE2, PHASE3
depression · DenmarkPHASE2, PHASE3
NCT03385538Clopidogrel Response and CYP2C19 Genotype in Ischemic Stroke Patients
stroke · DenmarkPHASE4
stroke · DenmarkPHASE4
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →